数据显示,Forxiga降低了2型糖尿病(T2D)患者发生心衰住院(hHF)或心血管(CV)死亡的复合风险。 原文出处:Forxiga approved in China for heart failure
图注：SGLT-2抑制剂诱导长寿机制的关键信号通路 拳打：胰岛素抵抗 衰老和代谢功能障碍是一个双向的过程。相关研究表明，SGLT-2抑制剂在逆转包括肥胖和胰岛素抵抗在内的代谢综合征方面具有深远的作用，可通过减少炎症生物标志物，实现模拟CR所导致的炎症减轻状态[4]。在对小鼠进行一段时间的SGLT-2抑制剂药物饲喂后，发...
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in pati
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been tested in adults and are approved for adults with type 2 diabetes, chronic kidney disease (CKD), and heart failure. However, they have not been tested in children with CKD in Europe and the USA. The European Medicines Agency (...
本文重点 * 首个且目前唯一获批用于治疗症状性慢性心力衰竭成人患者(无论患者射血分数如何)的SGLT-2抑制剂欧唐静®在华获批。 * 该适应症的获批基于 EMPEROR-Preserved...
Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approved for use in diabetes and heart failure, but...
Sotagliflozin: an insight into the first dual SGLT inhibitor now approved for heart failure Ir J Med Sci, 193 (2023) Google Scholar 66 D.L. Bhatt, M. Szarek, P.G. Steg, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure N Engl J Med, 384 (2) (2021...
hospitalization for heart failure [2]. The effect was clinically and statistically persuasive. 四型2型糖尿病患者的心血管结果试验表明,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂对预防严重心力衰竭事件的发生具有显著效果,主要是在没有先前...
Primary outcomes were all-cause mortality (ACM), cardiovascular death (CVD), all-cause hospitalization (ACH), and hospitalization for heart failure (HHF). SGLT2i class effects versus control were assessed via PMA and individual SGLT2i comparative efficacy via NMA plus ranking using p-scores. ...
Inhibition of SGLT2 lowers blood glucose by promoting the excretion of glucose into the urine, so SGLT2 was initially marketed as a treatment for diabetes. Subsequently, clinical studies demonstrated its efficacy in heart failure and chronic kidney disease30,31,32, and the indication was expanded;...